GEN Exclusives

More »

GEN News Highlights

More »
Jun 5, 2008

Transcription Factor Therapeutics Obtains Rights to Anesiva’s NF-kappa B Program

  • Anesiva out-licensed all rights to its NF-kappa B Decoy program to Transcription Factor Therapeutics (TFT). The deal could be worth up to $114 million if two products are commercialized.

    This fee covers an upfront license fee, with additional payments dependent on development and regulatory milestones. Anesiva is also be entitled to royalty payments upon successful commercialization of any drug candidate(s).

    The transaction includes clinical drug candidate Avrina™. TFT will be responsible for the future development of Avrina, an inhibitor of NF-kappa that has already been assessed in a Phase I study for treatment of atopic dermatitis. The firm hopes to commence a trial in IBD next year.

    In addition,  IP associated with the NF-kB Decoy program, which has applications in eczema, rheumatoid arthritis, and asthma, will be transferred to TFT.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »